Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Targeted Peptide-Drug Conjugates for Use Against Prostate Cancer

Publish date:: July 26, 2019

Key clinical point: Docetaxel was found to be less cytotoxic in all the cell lines as compared to drug alone.

Major finding: Doxorubicin (Dox) conjugate containing disulfide linkage showed comparable cytotoxicity vs Dox after 72-hour incubation in all the cancer cell lines, whereas it was found to be less cytotoxic on RWPE-1, suggesting that it can act as a Dox prodrug.

Study details: Researchers selected both the normal prostate cell line, RWPE-1, and the cancerous prostate cell lines, PC3, DU-145, LNCaP, and C4-2, to evaluate the anticancer activity of synthesized peptide-drug conjugates.

Citation:

Park SE, et al. Int J Mol Sci. 2019 Jul 4;20(13). doi: 10.3390/ijms20133291.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in Prostate Cancer

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,